"Sildenafil Citrate" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A PHOSPHODIESTERASE TYPE-5 INHIBITOR; VASODILATOR AGENT and UROLOGICAL AGENT that is used in the treatment of ERECTILE DYSFUNCTION and PRIMARY PULMONARY HYPERTENSION.
Descriptor ID |
D000068677
|
MeSH Number(s) |
D02.065.884.675 D02.886.590.700.675 D03.383.606.854 D03.633.100.759.824
|
Concept/Terms |
Sildenafil Citrate- Sildenafil Citrate
- Citrate, Sildenafil
- 1-((3-(6,7-Dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo(4,3-d)pyrimidin-5-yl)-4-ethoxyphenyl)sulfonyl)-4-methylpiperazine citrate
UK 92480-10- UK 92480-10
- UK 92480 10
- UK 9248010
- UK-92,480-10
- UK 92,480 10
|
Below are MeSH descriptors whose meaning is more general than "Sildenafil Citrate".
Below are MeSH descriptors whose meaning is more specific than "Sildenafil Citrate".
This graph shows the total number of publications written about "Sildenafil Citrate" by people in this website by year, and whether "Sildenafil Citrate" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
2004 | 0 | 1 | 1 |
2007 | 0 | 1 | 1 |
2008 | 0 | 1 | 1 |
2010 | 0 | 1 | 1 |
2013 | 0 | 1 | 1 |
2016 | 1 | 0 | 1 |
2017 | 9 | 4 | 13 |
2018 | 12 | 2 | 14 |
2019 | 2 | 4 | 6 |
2020 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Sildenafil Citrate" by people in Profiles.
-
The war against the SARS-CoV2 infection: Is it better to fight or mitigate it? Med Hypotheses. 2020 Oct; 143:110129.
-
COVID-19 in a Patient with ß-Thalassemia Major and Severe Pulmonary Arterial Hypertension. Hemoglobin. 2020 May; 44(3):218-220.
-
Three novel prevention, diagnostic, and treatment options for COVID-19 urgently necessitating controlled randomized trials. Med Hypotheses. 2020 Oct; 143:109851.
-
PDE5 Inhibition Stimulates Tie2-Expressing Monocytes and Angiopoietin-1 Restoring Angiogenic Homeostasis in Diabetes. J Clin Endocrinol Metab. 2019 07 01; 104(7):2623-2636.
-
Pharmacokinetics-Driven Optimization of 4(3 H)-Pyrimidinones as Phosphodiesterase Type 5 Inhibitors Leading to TPN171, a Clinical Candidate for the Treatment of Pulmonary Arterial Hypertension. J Med Chem. 2019 05 23; 62(10):4979-4990.
-
Switching from sildenafil to riociguat in patients with persistent or inoperable chronic thromboembolic pulmonary hypertension. Int J Cardiol. 2019 02 15; 277:239.
-
Deep vein thrombosis associated with sildenafil. Emergencias. 2019 02; 31(1):72.
-
Antenatal therapy with sildenafil: don't throw the baby out with the bathwater. Ultrasound Obstet Gynecol. 2019 02; 53(2):274-275.
-
Detailed statistical analysis plan for the Dutch STRIDER (Sildenafil TheRapy In Dismal prognosis Early-onset fetal growth Restriction) randomised clinical trial on sildenafil versus placebo for pregnant women with severe early onset fetal growth restriction. Trials. 2019 Jan 11; 20(1):42.
-
Probing the Effect of Sildenafil on Progesterone and Testosterone Production by an Intracellular FRET/BRET Combined Approach. Biochemistry. 2019 02 12; 58(6):799-808.